Roflumilast
Top View
- Respiratory: Bronchodilators for COPD
- Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
- Simvastatin Up-Regulates Adenosine Deaminase and Suppresses
- Bifunctional Drugs for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- Q3 2017,ERX.NPA.37 Roflumilast (Daliresp)
- Anti‑Inflammatory Effect of Ciclamilast in an Allergic Model Involving the Expression of PDE4B
- Roflumilast: a New Oral, Once-Daily Therapy for COPD Editor By: Mallary Wood, Pharm.D
- Roflumilast (Daliresp®) EOCCO POLICY
- Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.20 Line of Business: Medicaid Revision Log
- Inhaled Beta-Agonist Combination Agents
- Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke–Exposed Mice
- (12) Patent Application Publication (10) Pub. No.: US 2013/0252924 A1 Penninger Et Al
- Chronic Obstructive Pulmonary Disease (“COPD”) Medication Guide
- Drug Development for Asthma and COPD: a Regulatory Perspective
- Roflumilast Versus Theophylline for COPD
- Effect of Roflumilast on Exacerbations in Patients with Severe Chronic
- Justification
- Phosphodiesterase 4 Inhibition Reduces Lung Fibrosis Following Targeted Type II Alveolar Epithelial Cell Injury